Unibest

Pharmaceutical intermediates

Infigratinib Intermediates

1 pharmaceutical intermediate for Infigratinib. Indication: Achondroplasia.

Submit a ProjectAll intermediates

About Infigratinib

Originator
Novartis AG
Indication
Achondroplasia
Approved Date
05/28/2021
NCE Patent
05/28/2026
DS/DP
08/06/2028

Available intermediates

1 intermediate currently listed for Infigratinib. Request specifications, documentation or a quotation for any item below.

Infigratinib intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
2,6-Dichloro-3,5-dimethoxyaniline872509-56-3//

Other programs under I

Ibrutinib/ Zanubrutinib IguratimodImatinibImeglimin hydrochlorideIndacaterol MaleateIpatacopan HydrochlorideIpragliflozinIrinotecan

Building toward Infigratinib?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

Submit a Project Talk to the team

How can we help you?

Receive insights into the latest events and regulatory updates

Sent directly to your email

Get industry insights and Unibest news here

Contact Us →